Caribou Biosciences, Inc. (CRBU)
0.4232
-0.02
(-4.90%)
USD |
NASDAQ |
Oct 30, 16:00
0.43
+0.01
(+1.61%)
After-Hours: 20:00
Caribou Biosciences Enterprise Value : -40.80M for Oct. 30, 2026
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| October 30, 2026 | -40.80M |
| October 29, 2026 | -38.49M |
| October 28, 2026 | -33.78M |
| October 27, 2026 | -36.83M |
| October 26, 2026 | -33.49M |
| October 23, 2026 | -29.18M |
| October 22, 2026 | -26.30M |
| October 21, 2026 | -27.95M |
| October 20, 2026 | -30.65M |
| October 19, 2026 | -36.48M |
| October 16, 2026 | -35.85M |
| October 15, 2026 | -36.40M |
| October 14, 2026 | -36.89M |
| October 13, 2026 | -35.84M |
| October 12, 2026 | -32.99M |
| October 09, 2026 | -36.88M |
| October 08, 2026 | -34.65M |
| October 07, 2026 | -20.22M |
| October 06, 2026 | 34.65M |
| October 05, 2026 | 40.48M |
| October 02, 2026 | 43.66M |
| October 01, 2026 | 43.66M |
| September 30, 2026 | 48.96M |
| September 29, 2026 | 45.78M |
| September 28, 2026 | 44.72M |
| Date | Value |
|---|---|
| September 25, 2026 | 45.78M |
| September 24, 2026 | 46.84M |
| September 23, 2026 | 51.08M |
| September 22, 2026 | 56.38M |
| September 21, 2026 | 52.14M |
| September 18, 2026 | 52.14M |
| September 17, 2026 | 53.20M |
| September 16, 2026 | 46.84M |
| September 15, 2026 | 48.96M |
| September 14, 2026 | 51.08M |
| September 11, 2026 | 48.96M |
| September 10, 2026 | 59.56M |
| September 09, 2026 | 66.97M |
| September 08, 2026 | 77.57M |
| September 04, 2026 | 80.75M |
| September 03, 2026 | 80.75M |
| September 02, 2026 | 83.93M |
| September 01, 2026 | 78.63M |
| August 31, 2026 | 77.57M |
| August 28, 2026 | 86.05M |
| August 27, 2026 | 90.29M |
| August 26, 2026 | 89.23M |
| August 25, 2026 | 100.89M |
| August 24, 2026 | 88.17M |
| August 21, 2026 | 90.29M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Anavex Life Sciences Corp. | -8.017M |
| Intellia Therapeutics, Inc. | 1.382B |
| Vir Biotechnology, Inc. | 1.470B |
| Vaxcyte, Inc. | 7.610B |
| Foghorn Therapeutics, Inc. | -2.354M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -24.28M |
| Revenue (Quarterly) | 1.499M |
| Total Expenses (Quarterly) | 25.78M |
| EPS Diluted (Quarterly) | -0.2404 |
| Gross Profit Margin (Quarterly) | 58.31% |
| Profit Margin (Quarterly) | -1.62K% |
| Earnings Yield | -254.6% |
| Normalized Earnings Yield | -254.63 |